Results 181 to 190 of about 27,596 (292)

Decentralising Content Retrieval on the Decentralised Web

, 2023
openaire   +1 more source

Demand-Side Management for a Decentralised and Equitable Energy Transition in Aotearoa New Zealand. [PDF]

J R Soc N Z
Kamana-Williams B, Hooper RJ, Cerdeira AE, Chase JG.   +3 more
europepmc   +1 more source

The decentralisation defence

Computer Law & Security Review
openaire   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Participant satisfaction across three trial arms with varying degrees of decentralisation in the RADIAL proof-of-concept trial. [PDF]

Trials
Kopanz J, Zuidgeest MGP, Rutgrink L, Keighron C, Grobbee DE, Lagerwaard B, Trials@Home consortium.   +6 more
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Decentralising drug-resistant TB treatment initiation services. [PDF]

IJTLD Open
Murphy-Okpala N, Eze C, Orabueze IN, Ezenwosu I, Nwafor C, Ekeke N, Ezeakile O, Chukwu JN, Matiku S, Meka A, Njoku M, Kirubi B, Iyama F, Ossai E, Chijioke-Akaniro O, Creswell J.   +15 more
europepmc   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

How do communication, trust and professional relationships shape decentralised clinical trials? A qualitative interview study of international stakeholders. [PDF]

BMJ Open
Coyle J, Rogers A, Copland RR, Mackenzie IS.   +3 more
europepmc   +1 more source

Publicly funded private schools and academic achievement: A comparative analysis of PISA data in European countries

British Educational Research Journal, EarlyView.
Abstract This paper analyses differences in academic achievement associated with attendance at publicly funded private schools and public schools across 11 European countries. Using eight waves of PISA data (2000–2022), we apply OLS, IPW and IPWRA estimators to account for observed heterogeneity and mitigate selection bias.
Priya Maurya, Léonard Moulin, Denis Fougère   +2 more
wiley   +1 more source